07 November 2025

SUPPLEMENT DATED 07 NOVEMBER 2025 TO THE BASE PROSPECTUS DATED 10 JULY 2025

Aktia

AKTIA BANK PLC (Incorporated with limited liability in Finland)

€6,000,000,000

Euro Medium Term Note and Covered Bond Programme

This supplement is supplemental to, and must be read in conjunction with the base prospectus dated 10 July 2025 and supplement on it dated 07 August 2025 prepared by Aktia Bank plc with respect to its €6,000,000,000 Euro Medium Term Note and Covered Bond Programme and constitutes a supplement for the purposes of Article 23 (1) of Regulation (EU) No. 2017/1129 (The "Prospectus Regulation")

This supplement will be available for viewing on the website of the Luxembourg Stock Exchange (https://www.luxse.com/programme/Programme-AktiaBank/13744) and on the websites of Aktia Bank plc (https://www.aktia.com/en/investors/reports-and-presentations/year/2025).

Purpose of this Prospectus Supplement

Update of Managing Director and Executive Committee (Base prospectus page 159-160)

The subsection "The Managing Director and the other members of the Executive Committee "on page 160 of the base prospectus shall be deemed deleted and replaced with the following:

The Managing Director and the other members of the Executive Committee

Anssi Huhta, eMBA, President and CEO

Sakari Järvelä, M.Sc., (Econ.) Executive Vice President and Chief Financial Officer

Sini Kivekäs, LL.M., Executive Vice President, Group Functions

Pasi Vuorinen, Pol.Sc., CEFA, Executive Vice President, Asset Management

Oskari Kurki, M.Sc., (Tech), MBA Executive Vice President, CIO

Eva-Maria Broman-Rimpi, LL.M (deputy district judge), M.Sc (Econ), CRO

Ville Niiranen, LLL, Aktia Life Insurance Ltd, CEO

The business address at which the Managing Director and each of the other members of the Executive Committee can be contacted is Aktia Bank plc, Arkadiagatan 4-6 A, 00100 Helsingfors, FI-00100 Helsinki, Finland; visitors' address: Arkadiagatan 4-6 A, 4th floor, Helsinki.

Update of the Members of the Board of Directors

The section "Members of the Board of Directors" on page 159 of the base prospectus shall be deemed deleted and replaced with the following:

"The members of the Board of Directors are appointed for a period beginning from the General Meeting and ending at the next General Meeting. Appointments are prepared by a Shareholders' Nomination Board comprising representatives of the five largest shareholders.

Juha Hammarén,

Chair of the Board, member of the Board's Remuneration and Corporate Governance Committee and the Board's Audit Committee

LL.M. (with court training), EMBA

Joakim Frimoding,

Vice Chair of the Board, chair of the Board's Remuneration and Corporate Governance Committee and member of the Board's Risk Committee
Bachelor of Arts (Oxford)

Maria Jerhamre Engström,

Member of the Board, chair of the

Member of the Board, chair of the Board's Risk Committee eMBA

Harri Lauslahti.

Member of the Board, member of the Board's Risk Committee and Board's Remuneration and Corporate Governance Committee

M.Sc. (Econ.)

Sari Somerkallio,

Member of the Board, chair of the Board's Audit Committee

M.Sc. (Mathematics) and M.Sc. (Econ.)

Hanne Katrama,

Member of the Board, and member of the Board's Audit Committee

M.Sc. (Econ.)

The business address at which each of the Members of the Board can be contacted is Aktia Bank plc, Arkadiagatan 4-6 A, 00100 Helsingfors, FI-00100 Helsinki, Finland.

Update of Major Shareholders

The section "The Major Shareholders of the Issuer" on pages 160-161 of the base prospectus shall be deemed deleted and replaced with the following:

The major shareholders of the Issuer as on 30 September 2025 were:

Companies controlled by Erkki Etola 19.96 per cent. of the Issuer's issued shares

Veritas Pension Insurance Company Ltd: 8.24 per cent. of the Issuer's issued shares

Varma Mutual Pension Insurance Company: 4.68 per cent. of the Issuer's issued shares

Åbo Akademi University Foundation: 4.09 per cent. of the Issuer's issued shares

Mandatum Life Insurance Company Ltd: 2.97 per cent. of the Issuer's issued shares

Nordea Life Assurance Finland Ltd: 2.74 per cent. of the Issuer's issued shares

Stiftelsen Tre Smeder 2.34 per cent. of the Issuer's issued shares

Aktia Foundation Porvoo (Aktiastiftelsen i Borgå): 2.11 per cent. of the Issuer's issued shares

Aktia Foundation Vaasa (Aktiastiftelsen i Vasa): 1.80 per cent. of the Issuer's issued shares

Savingsbank Foundation Karjaa-Pohja (Sparbanksstiftelsen i Karis-Pojo) 1,29 per cent. of the Issuer's issued shares

In addition to the above the Issuer is not aware of any agreements, the operation of which may at a subsequent date result in major changes in ownership of its shares."

Update of Recent Developments

The section "Recent Developments" on page 157 of the base prospectus shall be deemed deleted and replaced with the following:

Aktia Bank Plc's incoming CEO Carl Haglund stepped down from his position and leave the company

The Board of Directors of Aktia Bank Plc concluded on the 15 September that the incoming CEO of the company Carl Haglund steps down from his position and leave the company. In the Board of Directors' assessment, Haglund no longer fulfills the prerequisites required to act as the company's CEO.

Aktia's interim CEO Anssi Huhta continued in his interim role until 21 Oct 2025.

Anssi Huhta appointed as new CEO of Aktia Bank Plc

Aktia Bank Plc's Board of Directors appointed Anssi Huhta as the new CEO of the company on the 21 October 2025. Huhta served as Aktia's interim CEO since 12 June 2025 and he took up his post immediately.

Decisions of Aktia Bank Plc's Extraordinary General Meeting and organising meeting of the Board of Directors

The Extraordinary General Meeting of Aktia Bank Plc was on 2 October 2025. The Extraordinary General Meeting supported all the proposals presented to the meeting. The minutes of the Annual General Meeting (in Swedish) are available on the company's website https://www.aktia.com/en/investors/corporate-governance/annual-general-meeting.

The Extraordinary General Meeting confirmed the number of board members as six.

Juha Hammarén was elected as a new member of the Board of Directors. The other members of the Board of Directors - Joakim Frimodig, Maria Jerhamre Engström, Hanne Katrama, Harri Lauslahti, and Sari Somerkallio - will continue in their roles in accordance with the resolution of the Annual General Meeting held on 3 April 2025. All board members were elected for a term of office continuing up until the end of the next Annual General Meeting.

Juha Hammarén is paid the annual remuneration for a member of the Board of Directors as resolved by the Annual General Meeting on 3 April 2025, proportionate to the length of his term, with the remuneration to be paid entirely in cash.

Organising meeting of the Board of Directors:

The Board of Directors, which convened after the General Meeting, elected Juha Hammarén as chair. Joakim Frimodig continues as the vice chair of the Board.

Juha Hammarén was elected as a member of the Board's Audit Committee as well as the Remuneration and Corporate Governance Committee, replacing Matts Rosenberg. No other changes were made to the composition of the committees.

The Board's committees are thus composed as follows:

- Audit Committee: Sari Somerkallio (Chair), Juha Hammarén and Hanne Katrama.
- Risk Committee: Maria Jerhamre Engström (Chair), Joakim Frimodig and Harri Lauslahti.

• Remuneration and Corporate Governance Committee: Joakim Frimodig (Chair), Juha Hammarén and Harri Lauslahti

General

Aktia Bank plc accepts responsibility for the information contained in this supplement. To the best of the knowledge of Aktia Bank plc (having taken all reasonable care to ensure that such is the case) the information contained in this supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Save as disclosed in this supplement, there has been no other significant new factor, material mistake or inaccuracy relating to information included in the base prospectus since the publication of the base prospectus and any other previously approved supplements.